$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Down 43.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Scholar Rock Holding Corporation (SRRK)
11:17am, Friday, 20'th May 2022
Scholar Rock Holding Corporation (SRRK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in rai
Scholar Rock Shares Jumps On Updating Strategic Priorities
12:37pm, Tuesday, 17'th May 2022
Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June. "Parting with employees who hav
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?
10:32am, Thursday, 24'th Mar 2022
Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving hig
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates
09:45am, Monday, 07'th Mar 2022
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline
04:06pm, Tuesday, 01'st Mar 2022
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference
07:30am, Friday, 25'th Feb 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament
Scholar Rock (SRRK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
09:11pm, Wednesday, 12'th Jan 2022 Seeking AlphaScholar Rock Holding Corp Shares Close in on 52-Week Low - Market Mover
08:13am, Monday, 10'th Jan 2022 Kwhen Finance
Scholar Rock Holding Corp (SRRK) shares closed today at 0.5% above its 52 week low of $21.31, giving the company a market cap of $751M. The stock is currently down 13.8% year-to-date, down 53.4% over the past 12 months, and up 38.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.6% The company's stock price performance over the past 12 months lags the peer average by 1.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Scholar Rock Holding Corp Shares Approach 52-Week Low - Market Mover
02:40pm, Saturday, 08'th Jan 2022 Kwhen Finance
Scholar Rock Holding Corp (SRRK) shares closed today at 0.5% above its 52 week low of $21.31, giving the company a market cap of $751M. The stock is currently down 13.8% year-to-date, down 54.6% over the past 12 months, and up 38.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 8.0% lower than its 5-day moving average, 13.8% lower than its 20-day moving average, and 27.0% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.6% The company's stock price performance over the past 12 months lags the peer average by 3.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Critical Comparison: Scholar Rock (NASDAQ:SRRK) versus PharmaCyte Biotech (OTCMKTS:PMCBD)
09:36am, Saturday, 11'th Dec 2021 Transcript Daily
Scholar Rock (NASDAQ:SRRK) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Analyst Recommendations This is a breakdown of recent ratings and target prices for Scholar Rock []
Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients
11:32am, Wednesday, 01'st Dec 2021 Benzinga
Scholar Rock Holding Corp (NASDAQ: SRRK ) announced the study design for the SAPPHIRE Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin. The trial will evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA). Study start-up activities for SAPPHIRE have commenced. Approximately 156 patients aged 2-12 years old with non-ambulatory Type 2/3 SMA will be enrolled in the primary efficacy population. Patients will Full story available on Benzinga.com
Credit Suisse AG Sells 1,345 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)
09:50am, Tuesday, 30'th Nov 2021 Transcript Daily
Credit Suisse AG reduced its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 9.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 13,264 shares of the companys stock after selling 1,345 shares during the period. Credit Suisse AGs holdings in Scholar Rock were worth $383,000 []
Thinking Of Selling Scholar Rock Holding Corporation (NASDAQ: SRRK) Stock? Read This First.
08:00pm, Saturday, 27'th Nov 2021 Stocks Register
Scholar Rock Holding Corporation (NASDAQ:SRRK) shares, rose in value on Friday, 11/26/21, with the stock price down by -0.95% to the previous days close as strong demand from buyers drove the stock to $26.97. Actively observing the price movement in the last trading, the stock closed the session at $27.23, falling within a range of Thinking Of Selling Scholar Rock Holding Corporation (NASDAQ: SRRK) Stock? Read This First. Read More »
Millennium Management LLC Purchases 132,956 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)
11:32am, Wednesday, 24'th Nov 2021 Transcript Daily
Millennium Management LLC lifted its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 325.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,839 shares of the companys stock after acquiring an additional 132,956 shares during the period. Millennium Management LLC owned 0.50% of Scholar Rock []
Sign In
Buy SRRK